Publications

CTD2 scientists at CSHL characterize intratumoral heterogeneity of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.   

CTD2 researchers at Dana Farber have identified the transcription factor ATXN1-CIC-ETS as a mediator of resistance to MAPK inhibitors in KRAS mutant pancreatic cancer cell lines using genome-scale CRISPR-Cas9 loss-Of-function screens. 

Scientists at Dana Farber have performed CRISPR-Cas9 drug resistance screens and identified that loss of KEAP1 expression negates inhibitors targeting RTK/MAPK pathways in Lung cancer. This finding may assist with treatment decisions in managing lung cancer. 

CTD2 scientists at Dana Farber have identified the serine/threonine kinase family member NEK6 as a central mediator in restoring sensitivity to hormone ablation in prostate cancer xenograft models.

CSHL CTD² scientists developed a method that allows temporal control of CRISPR/Cas9 by conjugating a destabilizing domain to Cas9. This robust high-throughput approach can be used for gene editing and to investigate interactions between functional genes.

The OncoPPi network is a resource of experimentally determined physical protein-protein interactions that builds on cancer genomics for discovery and exploitation of cancer vulnerabilities.